2025-12-24 - Analysis Report
Okay, here's a comprehensive analysis of Eli Lilly and Co. (LLY) based on the data you provided, broken down into the requested sections:

**1) Return Rate Comparison (LLY vs. S&P 500)**

*   **Eli Lilly and Co (LLY) Overview:** Eli Lilly is a global pharmaceutical company engaged in the discovery, development, manufacturing, and marketing of pharmaceutical products.
*   **LLY Cumulative Return:** 305.60%
*   **VOO (S&P 500) Cumulative Return:** 100.88%
*   **Divergence:** 204.7 (Current), (Max: 248.5, Min: -33.6), Relative Divergence: 84.5

**Analysis:** Eli Lilly has significantly outperformed the S&P 500. The current divergence of 204.7 percentage points represents a considerable outperformance. The relative divergence of 84.5 indicates that this outperformance is currently positioned in the upper range of its historical divergence from the S&P 500, implying a period of strong relative performance.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha  | Beta  | Cap(B) |
|------------|--------|-------|--------|-------|--------|
| 2015-2017  | 11.0%  | 76.1% | -17.0% | -0.0  | 75.7   |
| 2016-2018  | 39.0%  | 68.9% | 24.0%  | -0.0  | 103.8  |
| 2017-2019  | 41.0%  | 68.9% | 19.0%  | 0.4   | 117.8  |
| 2018-2020  | 34.0%  | 79.8% | 10.0%  | 0.4   | 151.4  |
| 2019-2021  | 53.0%  | 79.8% | 7.0%   | 0.5   | 247.7  |
| 2020-2022  | 64.0%  | 79.8% | 65.0%  | 0.4   | 328.0  |
| 2021-2023  | 125.0% | 78.9% | 124.0% | 0.2   | 522.7  |
| 2022-2024  | 134.0% | 81.2% | 113.0% | 0.2   | 692.2  |
| 2023-2025  | 197.0% | 83.5% | 132.0% | 0.2   | 960.7  |

**Analysis:**

*   **CAGR:**  Shows strong and accelerating growth in recent periods, with the CAGR reaching impressive levels in the last three years.
*   **MDD (Maximum Drawdown):** Relatively consistent across the periods, indicating a degree of volatility.
*   **Alpha:** The Alpha values are highly positive in recent years, especially from 2020 onwards, demonstrating that LLY's returns are exceeding what would be expected based on the market's (S&P 500) performance.
*   **Beta:** The Beta values are low, suggesting that LLY's price is not strongly correlated with the S&P 500 and may be less sensitive to overall market movements.
*   **Cap(B):**  Market capitalization has shown significant growth over the periods, indicating increasing investor confidence and valuation.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 1071.44
*   **Last Market:** Price: 1071.64, Previous Close: 1076.48, Change: -0.45
*   **5-day SMA:** 1057.32
*   **20-day SMA:** 1042.56
*   **60-day SMA:** 931.17

**Analysis:** The stock price is currently trading above all three moving averages (5-day, 20-day, and 60-day), which generally suggests an upward trend. The 5-day SMA is above the 20-day SMA, which is above the 60-day SMA, further reinforcing this bullish signal. The minor decrease in the last market day indicates a slight pullback but doesn't negate the overall positive trend.

**3) RSI, PPO, and Other Indicators**

*   **MRI (Market Risk Indicator):** 0.8 (Medium Investment Recommended)
*   **RSI:** 55.59
*   **PPO:** -0.23
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-11-03)
*   **Recent (20 days) relative divergence change:** 5.8 (+) (Short-term increase)
*   **Expected Return (%):** 49.2 (Expected excess return compared to S&P 500 if invested long-term)

**Analysis:**

*   **MRI:** Indicates a medium level of risk, suggesting that investment is reasonably safe but not without potential downside.
*   **RSI:** A value of 55.59 is neutral, not indicating overbought or oversold conditions.
*   **PPO:**  A slightly negative PPO (-0.23) suggests that the short-term moving average is slightly below the long-term moving average, indicating a potential for further upward momentum or a period of consolidation.
*   **Hybrid Signal:** The hybrid signal suggests a strong buy recommendation, indicating high confidence in the stock's prospects.
*   **Recent Divergence Change:** The increase in relative divergence over the past 20 days supports the observation of a recent upward trend.
*   **Expected Return:** The high expected return of 49.2% is a compelling factor for long-term investors.

**4) Recent News & Significant Events (Yahoo Finance)**

*   **Wegovy Pill Approval Raises Stakes:**  Positive news about potential expansion in the GLP-1 market with an oral version of Wegovy.
*   **Eli Lilly Stock Split:** A stock split can make shares more accessible to individual investors.
*   **Novo Nordisk's Obesity Pill Approval:** Potential competitive pressure as a rival gets approval for a similar product.
*   **Zepbound Price Slash:** Price adjustments may impact profitability, but could also increase market share.
*   **Triggers for Next Rally:** Indicates potential future growth catalysts for the stock.
*   **Stock Position Trimmed by Goelzer Investment Management Inc.:** Suggests some institutional investors are reducing their holdings, which could be a concern, but also possibly just profit-taking.

**Analysis:** The news highlights both opportunities and challenges. The potential for the Wegovy pill and triggers for the next rally are positive. However, increased competition and price adjustments are potential headwinds. The stock split generally signals confidence in future growth.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (1.70)
*   **Opinions:** 27
*   **Target Price (avg/high/low):** 1093.22 / 1500.00 / 770.00

**Analysis:** The strong buy consensus among analysts, combined with an average target price above the current price, suggests a positive outlook for the stock. The range of target prices reflects some uncertainty, but the overall sentiment is bullish.

**5) Recent Earnings Analysis**

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-10-30 | 6.22 | 17.60 B$   |
| 2025-08-07 | 6.3  | 15.56 B$   |
| 2025-05-01 | 3.07 | 12.73 B$   |
| 2024-10-30 | 1.08 | 11.44 B$   |
| 2025-10-30 | 1.08 | 11.44 B$   |

**Analysis:** Both EPS (Earnings Per Share) and revenue have shown significant growth over the past few quarters. The increasing EPS and revenue figures indicate strong financial performance and potential for continued growth.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30   | $17.60B    | 82.91%        |
| 2025-06-30   | $15.56B    | 84.27%        |
| 2025-03-31   | $12.73B    | 82.53%        |
| 2024-12-31   | $13.53B    | 82.24%        |
| 2024-09-30   | $11.44B    | 81.02%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE      |
|--------------|------------|----------|
| 2025-09-30   | $23.79B    | 23.46%   |
| 2025-06-30   | $18.27B    | 30.98%   |
| 2025-03-31   | $15.76B    | 17.50%   |
| 2024-12-31   | $14.19B    | 31.07%   |
| 2024-09-30   | $14.24B    | 6.81%    |

**Analysis:**

*   **Revenue & Profitability:** Revenue has consistently increased over the observed period, accompanied by very high and relatively stable profit margins (above 80%). This indicates strong pricing power and efficient operations.
*   **Capital & Profitability:** Equity has also been generally increasing, reflecting the company's growing value. ROE (Return on Equity) fluctuates but generally shows strong profitability relative to shareholder equity.

**7) Comprehensive Analysis**

Eli Lilly presents a compelling investment case based on this data.  The company has significantly outperformed the S&P 500, demonstrated by the high cumulative return and positive alpha. Recent stock performance shows an upward trend.  Financial metrics reveal strong revenue growth, high profit margins, and improving profitability. Analyst sentiment is positive, with a consensus "Buy" rating and a target price above the current market level.

However, investors should be aware of potential risks. While the technical indicators are generally positive, the slight dip in the last market day and the mixed news headlines suggest the possibility of short-term volatility. Increased competition in the obesity drug market and potential impacts from price adjustments are factors to monitor. Also, some institutional trimming of stock positions is also a point to consider.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.